Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Sarepta (SRPT) to $182 from $196 and keeps an Overweight rating on the ...

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...

Guggenheim lowered the firm’s price target on Sarepta (SRPT) to $112 from $150 and keeps a Buy rating on the shares. The firm, in its preview ...

US Stock Market on March 12: The Dow Jones Industrial Average, the S&P 500 and the Nasdaq Composite indices eked out mild gains amid choppy trade on Wednesday, in some respite for Wall Street bulls ...

The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have ...

Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Sarepta (SRPT) to $184 from $215 and keeps an Outperform rating on the ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...

LPL Financial LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 12.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 53,438 shares ...

U.S. President Donald Trump’s tariff announcements and the countermeasures declared by trade partners dominated the week, hitting Wall Street stocks to mark historic declines. The S&P 500 index was ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price reduced by Needham & Company LLC from $202.00 to $183.00 in a report published on Thursday,Benzinga reports. Needham & Company LLC ...